[Sneddon-Wilkinson disease: efficacy of intermittent adalimumab therapy after lost response to infliximab and etanercept]

Ann Dermatol Venereol. 2013 Dec;140(12):797-800. doi: 10.1016/j.annder.2013.07.012. Epub 2013 Aug 13.
[Article in French]

Abstract

Background: Sneddon-Wilkinson disease (SWD) is a rare chronic neutrophilic dermatosis. The first-line treatment is dapsone but resistance to treatment may sometimes pose a challenge.

Case report: We report a multidrug-resistant patient who responded dramatically before gradually losing response to infliximab and then etanercept. Complete remission was again obtained with adalimumab.

Discussion: Our case confirms the previously reported dramatic efficacy of anti-TNF biological agents in recalcitrant SWD but highlights the possibility of subsequent loss of response. Furthermore, it illustrates the efficacy of adalimumab in this indication.

Keywords: Adalimumab; Anti-TNF; Biothérapie anti-TNFalpha; Dermatose neutrophilique; Maladie de Sneddon-Wilkinson; Neutrophilic dermatosis; Sneddon-Wilkinson disease.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adalimumab
  • Aged
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Drug Administration Schedule
  • Drug Resistance
  • Drug Substitution
  • Etanercept
  • Humans
  • Immunoglobulin A / blood
  • Immunoglobulin G / pharmacology
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / pharmacology
  • Immunosuppressive Agents / therapeutic use
  • Infliximab
  • Male
  • Monoclonal Gammopathy of Undetermined Significance / complications
  • Neutrophil Infiltration
  • PUVA Therapy
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Skin Diseases, Vesiculobullous / complications
  • Skin Diseases, Vesiculobullous / drug therapy*
  • Skin Diseases, Vesiculobullous / immunology
  • Skin Diseases, Vesiculobullous / pathology
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin A
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab
  • Etanercept